EN | TR
E-ISSN: 3061-9947
Retrospective Evaluation of Sixty Five Year And Older Patients with Metastatic Colorectal Cancer
PDF
Cite
Share
Request
Original Article
VOLUME: 52 ISSUE: 3
P: 438-444
2019

Retrospective Evaluation of Sixty Five Year And Older Patients with Metastatic Colorectal Cancer

Acta Haematol Oncol Turc 2019;52(3):438-444
DOI: 10.5505/aot.2019.57441
Havva Yeşil Çınkır 1
Berna Öksüzoğlu 2
1. Gaziantep University Faculty Of Medicine, Department of Medical Oncology, Gaziantep, Turkey
2. Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
3.
No information available.
No information available
Received Date: 2018-09-21T18:14:57
Accepted Date: 2019-12-27T14:28:13
PDF
Cite
Share
Request

Abstract

INTRODUCTION

This study was planned with the aim of assessing general characteristics, performance status, applied treatments and survival rates of patients diagnosed with metastatic colorectal cancer (CRC) over the age of 65 years.

METHODS

This study was conducted between October 2010 and October 2014 at Dr. A.Y. Ankara Oncology Training and Research Hospital, Department of Medical Oncology Clinic. The files in the archives were scanned retrospectively and 139 patients diagnosed with colorectal cancer, who were 65 years or older in the metastatic stage were identified.

RESULTS

The median age of the patients was 73 (65-87). When evaluated according to age range, 81 (58.3%) of the patients were aged between 65-74, 53 (38.1%) were between 75-84 years and 5 (3.6%) were over 85 years old. The majority (57%) were male. Overall survival was 12.09 months (% 95 GA; 9.5-14.64). According to age range, median OS was 16.39 months between 65-74 years, 12.87 months (% 95 GA; 9.2-16.5 ) (p: 0.906) over 75 years.

DISCUSSION AND CONCLUSION

Advanced age should not be considered as a negative factor in planning treatment. After diagnosis and staging, multidisciplinary approach and treatment options should be applied considering personal wishes of the patient. Close and careful follow-up should be performed for toxicities that may be encountered, and supportive care should be applied when necessary.